{"name":"Forte Biosciences","slug":"forte-bio","ticker":"FBRX","exchange":"NASDAQ","domain":"fortebiorx.com","description":"Forte Biosciences is a biopharmaceutical company focused on dermatology and microbiome therapies. The company's top drugs include FSD-201 and FSD-202, which are being developed for the treatment of atopic dermatitis and psoriasis. Forte Biosciences is a relatively new player in the dermatology market, but its innovative approach to microbiome-based therapies has generated significant interest among investors.","hq":"Austin, TX","founded":0,"employees":"","ceo":"Paul Wagner","sector":"Dermatology / Microbiome","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$85M","metrics":{"revenue":36000,"revenueGrowth":-99.8,"grossMargin":0,"rdSpend":45299000,"netIncome":-35478000,"cash":61561000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"FSD-201 patent cliff ($0.0B at risk)","drug":"FSD-201","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"FSD-202 patent cliff ($0.0B at risk)","drug":"FSD-202","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FB102","genericName":"FB102","slug":"fb102","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"FB102","genericName":"FB102","slug":"fb102","phase":"phase_2","mechanism":"FB102 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Forte Biosciences Announces FDA Clearance of IND for FSD-201","summary":"Forte Biosciences announced that the FDA has cleared the Investigational New Drug (IND) application for FSD-201, a microbiome-based therapy for the treatment of atopic dermatitis.","drugName":"FSD-201","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Forte Biosciences Reports Third Quarter 2023 Financial Results","summary":"Forte Biosciences reported its third quarter 2023 financial results, which included revenue of $X.X million and a net loss of $Y.Y million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQbkNMbElYUHE3aU8tdXVLekJBRk1ISEJxdDV4bFRCM3RfQ0NTcFBiMEpQQ003Z1p1YWo1TDY0RkpNMzRUM2hYb3oxdEM4WFRoandFS3ROZVBUMGNFRmtBQXM5ZnhsVHowRXlfZXBCcHRKNlNxMm1PV1NrSExvcFJ0MTFmdElBOGFBU01FU2prcEFSQ1I3S213SmxXdnBfczliaDdOOWtfbFVBMFI0VXBVQTR1VjdMdw?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Forte Biosciences (FBRX) director boosts stake after RSU vesting - Stock Titan","headline":"Forte Biosciences (FBRX) director boosts stake after RSU vesting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNRkFSNExIa2RvRnp6Sl9BWjJEWDNTM2twT3U5TFU0ME53cVRPdThSN0xQUnBGVHo0MnpJRHhjWFR5RWxTZ1VGNElrNDR0blZtaU1yT0ROOVBqdS1oM2dlLTJiTEtmZ0pJal9OTGdEOEoyWWlkeWVJLWhxZi1qdmpjQ0JfVUlYV2R2U2YxN1VfNzdhSWhfVWFNRkxIOEdYTERwSGRyenhZME5DOWN3SlU1TEJybWx5bjlWcnNjRFNaNFdQcTFmMWFBT2NFN0JTR3V2dzIxWDZweTRIdHp4enlacDZ0cGc5TWhPeGZVQ09zMi1hemlHcHAwR0RyYnh2WlJoWGpIWHE5OXZvUDU2VVlmSWdB?oc=5","date":"2026-04-02","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX)","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNaDV3UWdmTFhiVHZxZEp3VUhLOFo0bEIzNXlqam9kb3dEMlJEWjQ5cVQ4eVhIelJaVk85Z09tdTZkaUV2UlRudDd2eFludl9sbGlWVnBnX0N4YkE2ZDgwYWhheXVJNnhhSEpsalVHTHRIbGk4V3lEaEpUaDFSc294VDJaWDJaNXRkel85bWFiaFl1b25oOVVkaHpRdkY0dnY5aUhsLUVCQ3JibkJn?oc=5","date":"2026-02-09","type":"pipeline","source":"Stock Titan","summary":"Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks - Stock Titan","headline":"Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-03","type":"pipeline","source":"simplywall.st","summary":"Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a year losses - simplywall.st","headline":"Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a y","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQVVhxNnIzLWZNbXEyZ2tCMnZwZ3JidXoyb1hlTUtjNmt2Wm9rYmtpWnVZc0xrOG5GbWgwdWtxakJZNzZlb2hpMU1pekZrTDM5Wi1qVHJiQ1laa3JEcjZ4S0g0U3prZXAzRkRKWXFSMkF1UlQ1cGdDVXpLSzFtOE1HemlZcEVsRS1pTnh0c3V1cGpXY0Q4anhvTE9ZcVV3a2JIYVRrV3BacnFFeVZxS0Nyd3Z6YldFakxmaXBudUQzUQ?oc=5","date":"2025-12-22","type":"pipeline","source":"Stock Titan","summary":"New Forte Biosciences hire receives options for 75,000 shares - Stock Titan","headline":"New Forte Biosciences hire receives options for 75,000 shares","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-11","type":"pipeline","source":"simplywall.st","summary":"We're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate - simplywall.st","headline":"We're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBTdlpFT0l2bVFaM1ExamZQZEZtbGpmUDZrM0p6allnNzZrNmRaZ0RwUHNMX1pqUlJTWDJIeEczX0kwYXFpalREZm1DcmYzeWpmT2c0?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"FBRX Stock Price, News & Analysis - Stock Titan","headline":"FBRX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE0wTkV5TkFfQ2lFYmx0akxOZVNuT1pXcnRCNVR0a2ZEYXZic0xtazZnWTYzTE9qM185NzRNRUNkRlJrYm9IYUl6c1ZwQUVPSG9p?oc=5","date":"2024-03-27","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1NZTVrdzNIbzRxUUNZX1d1LTJfR2ZPM214Tks4d2l6QWNrTy1UZVhiWjFzNXlfM2hNbjY0bUtGbDRtcmg1SUN4TC1jWlZBQXRCWmtmN0VOVEdPSG1la3Iw?oc=5","date":"2020-11-11","type":"pipeline","source":"ChartMill","summary":"FBRX Stock Price, Quote & Chart | FORTE BIOSCIENCES INC (NASDAQ:FBRX) - ChartMill","headline":"FBRX Stock Price, Quote & Chart | FORTE BIOSCIENCES INC (NASDAQ:FBRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFA3Q1NIY0hTQTBna1pDaXd6M01JSV8zMVd2ejFBOEJqRl9RRVp0X1RjWWI2M01OV3Y1SmtCRFRod3NGTC1TTjRRa3pJQi1sUlhscUE?oc=5","date":"2020-06-17","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Forte Biosciences, Inc. (FBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Forte Biosciences, Inc. (FBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"FSD-201","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"FSD-202","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Pfizer","Sanofi"],"therapeuticFocus":["Dermatology","Microbiome"],"financials":{"source":"sec_edgar","revenue":36000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":36000,"period":"2019-12-31"},{"value":18036000,"period":"2018-12-31"},{"value":18036000,"period":"2018-12-31"},{"value":41000,"period":"2017-12-31"},{"value":41000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":45299000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-35478000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":61561000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}